In conclusion, the present results revealed that patients harboring one or more alleles had a higher risk of neutropenia at initiation of treatment, indicating the importance of testing for UGT1A1 genetic polymorphisms before commencing therapy. The gene discussed is UGT1A1; the disease is neutropenia.